FDA
-
-
-
-
-
-
-
AbCellera (ABCL) -Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
-
-
-
-
-
-
-
AbCellera Reports Q3 2021 Business Results
-
-
-
-
-
-
-
AbCellera (ABCL) Gains Post-Market After FDA Expands Emergency Use Authorization of Bamlanivimab, Shares Up 18%
-
-
-
-
-
-
-
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
-
-
-
-
-
-
-
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
-
-
-
-
-
-
-
AbCellera (ABCL) -Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents
-
-
-
322,900 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

